Catalent Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 13, 2022 / 03:45PM GMT
Tejas Rajeev Savant - Morgan Stanley, Research Division - Equity Analyst

All right. My mic is on. I'm Tejas Savant. I'm the Life Science Tools and Diagnostics analyst at Morgan Stanley. It's my pleasure this afternoon to host Catalent. And from the company, we have Alessandro, Tom and Paul. So thank you all for doing this.

Before we get started, just need to wrap off the disclosure statement here. Please see the Morgan Stanley website at morganstanley.com/researchdisclosures. If you have any questions, do reach out to your sales rep.

Questions and Answers:

Tejas Rajeev Savant - Morgan Stanley, Research Division - Equity Analyst

So with that, Alessandro, maybe -- look, you've been at Catalent for a very long time, been in the hot seat for about 3 months now. Any early learnings you'd like to share? What has surprised you to the upside? And where do you think Catalent can do better as a company on a go-forward basis?

Alessandro Maselli - Catalent, Inc. - CEO & Director

Yes, sure. Number one, it's a
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot